Anti-Fibrinolytic Drugs - China

China

The Anti-Fibrinolytic Drugs market in China is projected to reach a revenue of €1.76bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 5.59%, resulting in a market volume of €2.31bn by 2029.
When compared globally, United States is predicted to generate the highest revenue with €9,141.00m in 2024.
China's robust pharmaceutical industry is driving the demand for anti-fibrinolytic drugs, as the country experiences a rise in cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

Anti-Fibrinolytic Drugs, also known as hemostatic agents, are used to control bleeding by preventing the breakdown of blood clots. In China, the Anti-Fibrinolytic Drugs market has been steadily growing in recent years.

Customer preferences: Chinese customers prefer Anti-Fibrinolytic Drugs due to their effectiveness in controlling bleeding during surgery and reducing the need for blood transfusions. Additionally, the increasing number of surgeries being performed in China has led to a higher demand for these drugs.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in China is the increasing adoption of these drugs in various surgical procedures, including cardiac surgeries, orthopedic surgeries, and liver surgeries. This trend is expected to continue as the number of surgeries being performed in China is projected to increase in the coming years.Another trend in the market is the development of new and improved Anti-Fibrinolytic Drugs. Pharmaceutical companies are investing in research and development to create more effective and safer drugs, which are expected to further drive market growth.

Local special circumstances: China has a large population with a high incidence of cardiovascular diseases, which has led to an increase in the number of cardiac surgeries being performed. Additionally, the aging population in China has also contributed to the growth of the Anti-Fibrinolytic Drugs market, as older adults are more likely to require surgery and are at a higher risk of bleeding complications.

Underlying macroeconomic factors: The Chinese government's focus on improving healthcare infrastructure and increasing access to medical care has also contributed to the growth of the Anti-Fibrinolytic Drugs market. Additionally, the increasing disposable income of the Chinese population has led to a higher demand for quality healthcare services, including surgical procedures and related medications.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.